Immunization

Overall rates of early-stage cervical cancer in the United States have been falling, but cases with advanced disease are continuing to rise.

Executives from CVS Health said they have multiple pathways in achieving a push to establish primary care services, provider enablement, and home health.

Francesca Ceddia, MD, senior vice president of respiratory vaccines at Moderna, said the company is in early stages of development for a combined mRNA vaccine for influenza, COVID-19, and RSV.

Francesca Ceddia, MD, senior vice president of respiratory vaccines at Moderna, discussed how mRNA vaccines could change the treatment landscape for respiratory illnesses.

A study suggests the paradigm of retail pharmacy is shifting, as customers are wanting more health and wellness-centered pharmacies as well as digital services.

Investigators find that establishing immunity in the mucosal areas establishes a frontline defense against these diseases.

A potential public health benefit of 13-valent pneumococcal conjugate vaccine is the reduction of acute chest syndrome among children with sickle-cell disease.

Experts predict a bad flu season in the US in 2022, noting children and pregnant women in their third trimester are recommended to be the first in line for flu vaccination.

Baloxavir marboxil is the first and only single-dose oral medicine to treat influenza in children, a population who play a significant role as transmitters of influenza in the country.

Tuberculosis affects millions of people worldwide, but the only known vaccine may only protect children who are 5 years of age or younger.

Approximately 6000 participants aged 5 years and older at 50 sites in different countries are set to received 3 doses of VLA 15 µg or the saline placebo, followed by a booster.

Immunoinformatics allows researchers to develop vaccines without microbial culturing, thus saving time and money.

Receiving a human papillomavirus vaccine and local surgical treatment could reduce the risk of recurring cervical lesions by 57%.

Michael Ganio, PharmD, MS, BCPS, FASHP, senior director of pharmacy practice and quality at ASHP, discussed the declaration of monkeypox as a public health emergency

The next-generation vaccine candidate, BNT162b5, consists of RNAs encoding enhanced prefusion spike proteins for the SARS-CoV-2 ancestral strain and an Omicron variant.

Young age was associated with vaccine-related fears that lowered vaccine uptake and increased symptoms of dizziness and lightheadedness during vaccination.

A majority of long-term care patients who received a fourth vaccination against COVID-19 were found to have increased protection against the omicron variant.

People who are afraid of shots or feel lightheaded and dizzy while near vaccine injection sites are less likely to get vaccinated against COVID-19.

Individuals vaccinated simultaneously with COVID-19 booster and influenza vaccines may be more likely to experience systemic reactions and adverse health impacts.

There are many changes that need to be made on multiple levels of healthcare to combat health disparities and equity.

Pharmacists are in an excellent position to educate and counsel patients on current recommendations.

Persistence by pharmacists and showing patients respect can help overcome misinformation.

The investigational PCV is designed to target serotypes responsible for 85% of all invasive cases of the disease in individuals aged 65 and older in the United States.

A pharmacist’s role in the ambulatory care setting has traditionally included a review of medications for potential drug-drug interactions and adverse events, medication reconciliation, and the provision of counseling services.

There is new guidance needed for pediatric immunizations, and pharmacists should be prepared for what's to come.

The FDA approved a licensure request for Fluzone High-Dose Quadrivalent, Flublok Quadrivalent, and Fluzone Quadrivalent for use in the upcoming 2022-2023 flu season, providing influenza vaccination for adults 65 years of age and older.

Rates of influenza and associated hospitalizations demand late-season vigilance.

Companies, FDA caught unaware by surge in virus cases, leading to shortage of critical items.

At 1 month, a 50-µg booster dose of mRNA-1273.214 had a potent neutralizing antibody response against the Omicron variants in all individuals, regardless of prior infection.